miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Gene Therapy

• Publication date

  2018-06-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41417-018-0031-4PMID 29925897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

  2017cited by this paper
• MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia

  2017cited by this paper
• Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

  2017cited by this paper
• Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

  2016cited by this paper
• A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer

  2016cited by this paper
• Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al

  2016cited by this paper
• Trastuzumab in the Treatment of Breast Cancer

  2016cited by this paper
• Triple-negative breast cancer: treatment challenges and solutions

  2016cited by this paper
• Expression and regulatory effects of microRNA-182 in osteosarcoma cells: A pilot study

  2016cited by this paper
• MiR-182 promotes proliferation and invasion and elevates the HIF-1α-VEGF-A axis in breast cancer cells by targeting FBXW7.

  2016cited by this paper
• Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

  2016cited by this paper
• Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint.

  2016cited by this paper
• Breast cancer intrinsic subtype classification, clinical use and future trends.

  2015cited by this paper
• Roles of miR-182 in sensory organ development and cancer

  2015cited by this paper
• The Downregulation of MiR-182 Is Associated with the Growth and Invasion of Osteosarcoma Cells through the Regulation of TIAM1 Expression

  2015cited by this paper
• miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma

  2015cited by this paper
• Drug Resistance in Cancer: An Overview

  2014cited by this paper
• MicroRNAs in cancer: biomarkers, functions and therapy.

  2014cited by this paper
• Triple negative 乳癌の細胞学的検討

  2013cited by this paper
• Overexpressed MicroRNA-182 Promotes Proliferation and Invasion in Prostate Cancer PC-3 Cells by Down-Regulating N-myc Downstream Regulated Gene 1 (NDRG1)

  2013cited by this paper
• HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials.

  2013cited by this paper
• Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK.

  2013cited by this paper
• Met interacts with EGFR and Ron in canine osteosarcoma.

  2013cited by this paper
• Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

  2012cited by this paper
• Treatment of HER2-positive breast cancer: current status and future perspectives

  2012cited by this paper
• An overview of the c-MET signaling pathway

  2011cited by this paper
• Emerging role of microRNAs in drug-resistant breast cancer.

  2011cited by this paper
• HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

  2011cited by this paper
• MicroRNA and drug resistance

  2010cited by this paper
• HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer

  2010cited by this paper
• Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

  2010cited by this paper
• Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.

  2010cited by this paper
• A Brief Review on the Mechanisms of miRNA Regulation

  2009cited by this paper
• Molecular and Physiologic Mechanisms of Drug Resistance in Cancer: An Overview

  2004cited by this paper
• P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells

  2004cited by this paper
• P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

  2004cited by this paper
• The genetic viewpoint

  1931cited by this paper

• LncRNA TUSC7 Inhibits Cell Proliferation in Chronic Lymphocytic Leukemia by Modulating the miR‐211‐5p/SLC37A3 Axis

  2025cites this paper
• Knockdown of miR-182 changes the sensitivity of triple-negative breast cancer cells to cisplatin

  2025cites this paper
• Investigating the interplay between the mir-183/182/96 cluster and the adherens junction pathway in early-stage breast cancer

  2024cites this paper
• Exosomal miR-182-5p from breast cancer cells reprogram tumor-associated macrophages and promote triple-negative breast cancer progression by targeting Notch1 in macrophages

  2024cites this paper
• Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers

  2024cites this paper
• Traditional Plant-Derived Compounds Inhibit Cell Migration and Induce Novel Cytoskeletal Effects in Glioblastoma Cells

  2024cites this paper
• MACC1 as a Potential Target for the Treatment and Prevention of Breast Cancer

  2023cites this paper
• Landscape of NcRNAs involved in drug resistance of breast cancer

  2023cites this paper
• miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review

  2023cites this paper
• The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target

  2023cites this paper
• Interplay between LncRNAs and microRNAs in Breast Cancer

  2023cites this paper
• Analysis of miRNAs: Biomarkers for HER2-Targeted Breast Cancer Therapy

  2023cites this paper
• miR-182 targeting reprograms tumor-associated macrophages and limits breast cancer progression

  2022cites this paper
• An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer

  2022cites this paper
• Clinical Application of MicroRNAs in Breast Cancer Treatment

  2022cites this paper
• Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR.

  2021cites this paper
• Breast Cancer Response to Therapy: Can microRNAs Lead the Way?

  2021cites this paper
• miR-182-5p enhances cisplatin resistance in epithelial ovarian cancer by downregulating GRB2

  2021cites this paper
• MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer.

  2021cites this paper
• The regulatory role of pivotal microRNAs in the AKT signaling pathway in breast cancer.

  2021cites this paper
• Gene therapy: A promising approach for breast cancer treatment

  2021cites this paper
• Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy

  2020cites this paper
• ΜiR-182-5p functions as a tumor suppressor to sensitize human ovarian cancer cells to cisplatin through direct targeting the cyclin dependent kinase 6 (CDK6).

  2020cites this paper
• New Insights into the Regulatory Role of lncRNA, circRNA, piRNAs, and ceRNAs in Ischemic Stroke

  2020cites this paper
• Coding the noncoding: 2 years of advances in the field of microRNAs and long noncoding RNAs

  2020cites this paper
• PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers

  2020cites this paper
• miR‐126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells

  2020cites this paper
• Anti-tumor Activity of Bufalin by Inhibiting c-MET Mediated MEK/ERK and PI3K/AKT Signaling Pathways in Gallbladder Cancer

  2020cites this paper
• Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction.

  2020cites this paper
• MiR-935 Promotes Clear Cell Renal Cell Carcinoma Migration and Invasion by Targeting IREB2

  2019cites this paper
• CMAR_A_232380 10891..10900

  2019cites this paper
• Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers.

  2019cites this paper